ABUS

3.21

0.00% 0.00

Dopo l'orario di chiusura: 3.21

Arbutus Biopharma Corp (ABUS)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario

Precedente Chiudi:

$3.21

Aprire:

$3.18

Volume 24 ore:

2.57M

Relative Volume:

2.77

Capitalizzazione di mercato:

$608.27M

Reddito:

$12.99M

Utile/perdita netta:

$-74.39M

Rapporto P/E:

-6.9783

EPS:

-0.46

Flusso di cassa netto:

$-78.92M

1 W Prestazione:

-7.76%

1M Prestazione:

-6.69%

6M Prestazione:

+8.81%

1 anno Prestazione:

+45.25%

Intervallo 1D:

$3.16

$3.26

Intervallo di 1 settimana:

$3.13

$3.605

Portata 52W:

$2.21

$4.725

Arbutus Biopharma Corp Stock (ABUS) Company Profile

Nome

Arbutus Biopharma Corp

Settore

Healthcare (1176)

Industria

Biotechnology (673)

Telefono

604-419-3200

Indirizzo

701 VETERANS CIRCLE, WARMINSTER, PA

Dipendente

Cinguettio

@arbutusbio

Prossima data di guadagno

2024-11-06

Ultimi documenti SEC

ABUS's Discussions on Twitter

Confronta ABUS con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ABUS Arbutus Biopharma Corp	3.21	608.27M	12.99M	-74.39M	-78.92M	-0.44
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Arbutus Biopharma Corp Stock (ABUS) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2022-02-02	Aggiornamento	Jefferies	Hold → Buy
2021-02-25	Iniziato	Jefferies	Hold
2020-12-17	Iniziato	H.C. Wainwright	Buy
2020-07-27	Ripresa	JMP Securities	Mkt Outperform
2020-07-24	Downgrade	Robert W. Baird	Outperform → Neutral
2020-05-19	Aggiornamento	Wedbush	Neutral → Outperform
2020-03-06	Aggiornamento	Chardan Capital Markets	Neutral → Buy
2020-02-20	Iniziato	Robert W. Baird	Outperform
2020-02-05	Aggiornamento	JMP Securities	Mkt Perform → Mkt Outperform
2019-10-07	Reiterato	B. Riley FBR	Buy
2019-10-04	Downgrade	Chardan Capital Markets	Buy → Neutral
2018-10-16	Aggiornamento	B. Riley FBR	Neutral → Buy
2018-10-15	Aggiornamento	Wedbush	Underperform → Neutral
2018-10-12	Reiterato	Chardan Capital Markets	Buy
2018-07-06	Downgrade	B. Riley FBR, Inc.	Buy → Neutral
2018-03-19	Ripresa	Chardan Capital Markets	Buy
2018-03-19	Downgrade	Wedbush	Outperform → Neutral
2018-01-05	Iniziato	B. Riley FBR, Inc.	Buy
2017-04-04	Aggiornamento	Chardan Capital Markets	Neutral → Buy
2017-02-01	Reiterato	Wedbush	Outperform
2016-12-13	Downgrade	Chardan Capital Markets	Buy → Neutral
2016-11-30	Aggiornamento	Chardan Capital Markets	Neutral → Buy

Mostra tutto

Arbutus Biopharma Corp Borsa (ABUS) Ultime notizie

Dec 20, 2024

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Takes Position in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

Dec 20, 2024

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Invests $754,000 in Arbutus Biopharma Co. (NASDAQ:ABUS) - MarketBeat

Dec 20, 2024

Dec 16, 2024

Arbutus Biopharma's SWOT analysis: hepatitis B focus drives stock potential - Investing.com

Dec 16, 2024

Arbutus Biopharma (NASDAQ:ABUS) Shares Gap DownHere's Why - MarketBeat

Dec 16, 2024

Dec 14, 2024

Charles Schwab Investment Management Inc. Purchases 831,663 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - MarketBeat

Dec 14, 2024

Dec 08, 2024

Intech Investment Management LLC Takes Position in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

Dec 08, 2024

Dec 06, 2024

Large Shareholder Urges Warminster-based Arbutus to Seek Partners Instead of Selling More Stock - BUCKSCO.Today

Dec 06, 2024

Here’s Why Arbutus (ABUS) Surged in Q3 - Yahoo Finance

Dec 06, 2024

Dec 04, 2024

Arbutus Biopharma's SWOT analysis: focus on CHB treatment drives stock outlook - Investing.com

Dec 04, 2024

Dec 03, 2024

Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors - The Bakersfield Californian

Dec 03, 2024

Arbutus Biopharma's HBV Trial Hits 50% Cure Rate; Major Investor Urges Strategic Partnership - StockTitan

Dec 03, 2024

Dec 02, 2024

Arbutus Biopharma Co. (NASDAQ:ABUS) Short Interest Update - MarketBeat

Dec 02, 2024

Dec 01, 2024

Arbutus Biopharma (STU:I9DN) 9-Day RSI : 39.19 (As of Dec. 01, 2024) - GuruFocus.com

Dec 01, 2024

Nov 27, 2024

Principal Financial Group Inc. Reduces Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

Nov 27, 2024

Nov 26, 2024

Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat - Yahoo Finance

Nov 26, 2024

Nov 25, 2024

Arbutus Biopharma (FRA:I9DN) Price-to-Operating-Cash-Flow : (As of Nov. 25, 2024) - GuruFocus.com

Nov 25, 2024

Nov 22, 2024

Arbutus Biopharma (STU:I9DN) Days Inventory : 0.00 (As of Sep. 2024) - GuruFocus.com

Nov 22, 2024

Nov 21, 2024

Arbutus Biopharma (STU:I9DN) Long-Term Debt & Capital Lease Obligation : €0.88 Mil (As of Sep. 2024) - GuruFocus.com

Nov 21, 2024

Nov 20, 2024

Arbutus Biopharma (NASDAQ:ABUS) Earns "Buy" Rating from Chardan Capital - MarketBeat

Nov 20, 2024

Nov 18, 2024

HC Wainwright Reiterates Buy Rating for Arbutus Biopharma (NASDAQ:ABUS) - MarketBeat

Nov 18, 2024

Nov 17, 2024

Arbutus Biopharma’s Clinical Trial Shows Promise for Hepatitis B Treatment - MyChesCo

Nov 17, 2024

Arbutus Biopharma Announces Positive Data from Clinical Trials at AASLD – The Liver Meeting® 2024 - Defense World

Nov 17, 2024

Promising New Data from Hepatitis B Trial by Arbutus and Barinthus - MyChesCo

Nov 17, 2024

Arbutus Biopharma Co. (NASDAQ:ABUS) Short Interest Down 16.0% in October - Defense World

Nov 17, 2024

Nov 16, 2024

ArriVent BioPharma Reports Advancements and Q3 2024 Financial Results - MyChesCo

Nov 16, 2024

Arbutus Biopharma to Showcase Innovations at Jefferies London Healthcare Conference - MyChesCo

Nov 16, 2024

Nov 15, 2024

Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon - Yahoo Finance

Nov 15, 2024

Nov 14, 2024

Two Seas Capital LP Adjusts Stake in Arbutus Biopharma Corp - GuruFocus.com

Nov 14, 2024

Arbutus to Present at Jefferies London Healthcare Conference - Yahoo Finance

Nov 14, 2024

Nov 12, 2024

Creative Planning Raises Stock Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

Nov 12, 2024

Nov 11, 2024

HC Wainwright Has Negative Forecast for ABUS FY2024 Earnings - MarketBeat

Nov 11, 2024

HC Wainwright Expects Weaker Earnings for Arbutus Biopharma - Defense World

Nov 11, 2024

Nov 09, 2024

HC Wainwright Reaffirms “Buy” Rating for Arbutus Biopharma (NASDAQ:ABUS) - Defense World

Nov 09, 2024

Nov 08, 2024

Arbutus Biopharma 8-K Filing: Financial Results and Corporate Presentation Update - Defense World

Nov 08, 2024

Arbutus Biopharma Corporation (NASDAQ:ABUS) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 08, 2024

Arbutus Biopharma (NASDAQ:ABUS) Stock Price Expected to Rise, Chardan Capital Analyst Says - Defense World

Nov 08, 2024

Nov 07, 2024

HC Wainwright Reaffirms Buy Rating for Arbutus Biopharma (NASDAQ:ABUS) - MarketBeat

Nov 07, 2024